Tredje Ap Fonden Nektar Therapeutics Transaction History

Tredje Ap Fonden

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 11, 2020	SELL	$14.47 - $27.96 $130,027 - $251,248	-8,986 Closed	0 $0
Q4 2019 Feb 10, 2020	SELL	$15.87 - $23.12 $95,124 - $138,581	-5,994 Reduced 40.01%	8,986 $194,000
Q3 2019 Nov 12, 2019	BUY	$16.91 - $36.27 $130,477 - $279,859	7,716 Added 106.22%	14,980 $273,000
Q2 2019 Aug 09, 2019	SELL	$31.0 - $36.3 $275,001 - $322,017	-8,871 Reduced 54.98%	7,264 $258,000
Q1 2019 May 10, 2019	BUY	$31.58 - $46.35 $102,034 - $149,756	3,231 Added 25.04%	16,135 $542,000

Q4 2018 Feb 11, 2019	BUY	$30.43 - $56.65 $298,183 - $555,113	9,799 Added 315.59%	12,904 $424,000
Q3 2018 Nov 13, 2018	BUY	$46.46 - $68.49 $144,258 - $212,661	3,105 New	3,105 $189,000

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $231M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Tredje Ap Fonden, based on Form 13F filings with the SEC.

Stay updated on Tredje Ap Fonden with notifications on news.